Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Pharming Group N.V.
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
October 20, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group provides update on previously announced G&A expense reduction plan
October 06, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
October 01, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group promoted to the Euronext AMX® index
September 10, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
September 02, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group reports second quarter and first half 2025 financial results and provides business update
July 31, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
June 24, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group reports first quarter 2025 financial results and provides business update
May 08, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
April 25, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
April 23, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
March 20, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
March 13, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
March 04, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group to participate in March investor conference
February 28, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group to report fourth quarter and full year 2024 financial results on March 13
February 27, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group to participate in February investor conference
February 10, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
January 21, 2025
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming announces public cash offer to the shareholders of Abliva AB
December 15, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming announces positive topline data in pediatric clinical trial of leniolisib
December 11, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group to participate in November investor conference
November 05, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group reports third quarter 2024 financial results and provides business update
October 24, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group to report third quarter 2024 financial results on October 24
October 10, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
October 10, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
September 26, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group to participate in September investor conferences
September 04, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group reports second quarter and first half 2024 financial results and provides business update
August 01, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group to report second quarter and first half 2024 financial results on August 1
July 18, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group to participate in June investor conferences
June 03, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
May 21, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Pharming Group to participate in May investor conference
May 20, 2024
From
Pharming Group N.V.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today